The following items were addressed at the Annual General Meeting of Diamyd Medical AB (publ) held today: Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end. The Company's income statement and balance sheet were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2012/2013 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2012/2013 fiscal year. Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa Essen-Möller and Erik Nerpin were re-elected to the Board. The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board. The Annual General Meeting resolved to re-elect the auditing company PricewaterhouseCoopers AB until the end of the Annual General Meeting 2014. Principal auditor is the authorized public accountant Eva Blom. The AGM resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs. For further information, please contact: Peter Zerhouni, President and CEO Diamyd Medical AB Phone: +46 8 661 00 26. E-mail: press@diamyd.com About Diamyd Medical Diamyd Medical is a Swedish diabetes company. The Company’s primary development project consists of the GAD-based diabetes vaccine Diamyd®for the treatment and prevention of autoimmune diabetes. Two Swedish researcher-initiated Phase II studies with Diamyd®are ongoing. One study evaluates whether the diabetes vaccine can prevent type 1 diabetes in children who are at high risk of developing the disease, while the other study evaluates whether Diamyd®in combination with relatively high doses of vitamin D and ibuprofen can preserve the body's own ability to regulate the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes. In May 2013 the Company concluded an exclusive licensing agreement with the University of California in Los Angeles (UCLA) relating to a patent portfolio for the therapeutic use of GABA (gamma-aminobutyric acid) and GABA receptor agonists for the treatment and prevention of type 1 and type 2 diabetes and other inflammation-related conditions, such as metabolic syndrome, rheumatoid arthritis and allergies. Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (US). Diamyd Medical’s Series B share is traded on NASDAQ OMX First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. Further information is available on the Company’s website: www.diamyd.com. Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797.
Bulletin from Annual General Meeting of Diamyd Medical AB
Top 10 Most Recent News Articles
Encompass Health: Leader in Rehabilitation Again in 2026
Pinnacle of Rehab: Encompass Health's Notable Streak You know, in a world where healthcare accolades fly around like confetti, Encompass Health Corp's persistence in being named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek for the seventh straight year is something to chew on. The fact that a record 78 of its hospitals dotted across 32 states...
Continue Reading
Spire's Year-End Call: Eyes on Earnings & Guidance
Anticipation Builds for Spire's Upcoming Earnings Call If you're keen on natural gas and the energy sector, keep a firm grip on your coffee cup because Spire Inc. (NYSE: SR) is about to spill the beans on their fiscal 2026 financials. Mark your calendars for November 17. Whether you're tuning in via phone or hitching a ride on the webcast, you're in for an earful. Time...
Continue Reading
Food Trends Tease: 2027 sofi™ Awards' 75 Finalists
The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...
Continue Reading
OppFi Readies Q3 Earnings; Investors Eye Financials
What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...
Continue Reading
Dickinson Brands Celebrates Witch Hazel Legacy with Event
Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...
Continue Reading
Senté’s Heparan Sulfate Pairing: Peer-Reviewed Success
Senté's Science-Driven Approach in Skincare Alright, cutting through the skincare noise, Senté Labs has pulled off something impressive—not just another jar of promises but actual, peer-reviewed science backing their Defense C Serum. Published in the Journal of Cosmetic Dermatology, this study isn't just talk about ingredients; it's a show of real results. This isn't...
Continue Reading
LINC Lawsuit: Boardroom Stumbles Spark Investor Action
Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...
Continue Reading
INSPIRE 2026: Luxury Hotel Trends and Investments
Luxury Hotels: Where's the Money Headed? All eyes on Orlando this December 15–16, where the International Luxury Hotel Association (ILHA) is calling the shots. INSPIRE 2026 is the marquee event of the year for luxury hospitality, and it ain't just about starry chandeliers and velvet drapes. We're talking real capital shifts, margins pinching tighter, and a future...
Continue Reading
PrePass Intelligence: A Game-Changer for Fleets
Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...
Continue Reading
Kenneth Smith Takes Helm for Trends Int’l Expansion
Tired of the Same Old Leadership Shuffle? Here Comes Kenneth Smith Look, I’ve seen my share of execs come and go, usually dragging the same old briefcase of stale ideas. But Kenneth Smith stepping up as CEO of Trends International? Now that’s got some real teeth to it. Come May 2026, he’s the guy at the helm, and he's got one hell of a to-do list. Smith's Roadmap: A...
Continue Reading
